Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
复制标题
DOI：
10.1177/15347354211032283
复制
发表时间：
2021-01
影响因子：
2.9
通讯作者：
Goncalves MD
中科院分区：
文献类型：
--
作者：
Blow T;Hyde PN;Falcone JN;Neinstein A;Vasan N;Chitkara R;Hurd MA;Sardesai S;Lustberg MB;Flory JH;Volek JS;Goncalves MD
Alpelisib是一种α-选择性磷脂酰肌醇3-激酶（PI 3 K）抑制剂，获批用于治疗绝经后女性和男性激素受体阳性（HR+）、人表皮生长因子受体2阴性（HER 2-）、PIK 3CA突变的晚期乳腺癌（ABC）。高血压是一种常见的靶向不良反应，会损害治疗疗效，并增加治疗延迟、剂量减少和停药的发生率。目前，对于二甲双胍无效时如何管理alpelisib引起的高血糖症尚无明确的指南。在本病例系列中，我们回顾了3例ABC受试者，他们在alpelisib-fulvestrant治疗期间发生高血糖，并通过饮食和药物干预成功管理。这些病例提供了轶事证据，支持在alpelisib治疗期间使用钠-葡萄糖协同转运蛋白-2抑制剂（SGLT 2 i）和极低碳水化合物饮食以最大限度地降低高血糖症。
Alpelisib is a α-selective phosphatidylinositol 3-kinase (PI3K) inhibitor approved for treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–), PIK3CA-mutated, advanced breast cancer (ABC). Hyperglycemia is a common, on-target adverse effect that impairs treatment efficacy and increases the rate of treatment delays, dose reductions, and discontinuation. Currently, there are no clear guidelines on how to manage hyperglycemia due to alpelisib when metformin is not effective. In this case series, we review 3 subjects with ABC that developed hyperglycemia during alpelisib-fulvestrant therapy and were successfully managed with dietary and pharmacologic interventions. These cases provide anecdotal evidence to support the use of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and very low carbohydrate diets to minimize hyperglycemia during alpelisib therapy.
登录
查看更多内容
DOI：
10.1158/1055-9965.epi-16-0889
发表时间：
2017-06
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Mariotto AB;Etzioni R;Hurlbert M;Penberthy L;Mayer M
通讯作者：
Mayer M
影响因子：
254.7
作者：
Siegel, Rebecca L.;Miller, Kimberly D.;Jemal, Ahmedin
通讯作者：
Jemal, Ahmedin
影响因子：
158.5
作者：
Andre, Fabrice;Ciruelos, Eva;Juric, Dejan
通讯作者：
Juric, Dejan
影响因子：
5.2
作者：
Athinarayanan, Shaminie J.;Adams, Rebecca N.;McCarter, James P.
通讯作者：
McCarter, James P.
影响因子：
9.3
作者：
Athinarayanan SJ;Hallberg SJ;McKenzie AL;Lechner K;King S;McCarter JP;Volek JS;Phinney SD;Krauss RM
通讯作者：
Krauss RM